Medrol (Methylprednisolone) Tapering in Rheumatoid Arthritis

Role of Glucocorticoids in RA

Methylprednisolone Dose Equivalence

Starting Doses in RA

• Oral: up to prednisone 30 mg/day equivalent (= Medrol ~24 mg/day), though typical practice uses lower: 8–16 mg/day
• Single IM injection: methylprednisolone 120 mg (Depo-Medrol)
• IV pulse: 250 mg methylprednisolone single dose

Tapering Schedule

Short course (acute flare, <2–4 weeks use)

Bridging course (DMARD initiation, typical 3–6 months)

Chronic low-dose GC (if long-term use necessary)

• Reduce by 1 mg every 4–8 weeks
• At doses ≤4 mg/day: taper even more slowly (1 mg every 2–3 months)
• The SEMIRA trial showed that ~2/3 of RA patients on tocilizumab + prednisone 5 mg/day were able to taper off without a flare; one-third experienced flares requiring restart

Key Clinical Principles

1. Taper is guided by disease activity - use DAS28 or clinical assessment; do not taper mechanically if disease remains active
2. EULAR 2025 recommends GCs as short-term bridge alongside MTX; goal is discontinuation, not long-term use
3. Attempted GC tapering should be done for any patient in low disease activity - many can successfully stop
4. Worsening on taper = consider DMARD adjustment or biologic escalation, not just restarting GCs
5. Below physiologic threshold (~Medrol 3 mg/day = prednisone ~4 mg/day): taper very slowly to avoid HPA axis insufficiency; consider morning cortisol assessment if concerned
6. Infection risk even at low doses (≤Medrol 4 mg/day = prednisone 5 mg/day) - counsel patients accordingly
7. Always co-prescribe bone protection (calcium + vitamin D; consider bisphosphonate) for courses >3 months

Routes in Bridging

2025 EULAR Update (Current Guidance)

Once-Weekly Medrol (Methylprednisolone) in RA - Tapering Guide

Why Once Weekly?

1. Given alongside weekly MTX - the steroid blunts MTX side effects (nausea, fatigue) and provides a burst of anti-inflammatory cover on the active treatment day
2. Low-frequency bridging - for patients who cannot or will not take daily steroids, a weekly pulse provides periodic inflammation control

Typical Starting Doses (Once Weekly)

Tapering Schedule - Once Weekly Dosing

Key Points for Once-Weekly Dosing

1. HPA suppression risk is lower with once-weekly dosing compared to daily dosing - abrupt stopping is generally safer, but still taper if used for >3 months
2. Reduce by 4 mg (1 tablet) per step - do not halve the dose abruptly
3. Taper trigger: disease in low activity or remission on DAS28; if DAS28 remains elevated, do not taper - escalate DMARD instead
4. If flare occurs on taper: step back up one dose level for 4 weeks, then retry taper
5. No need to give on an empty stomach - once-weekly dosing is usually with food on MTX day
6. HPA axis: once-weekly doses of ≤8 mg Medrol are unlikely to cause clinically significant adrenal suppression; abrupt discontinuation is generally safe at this dose level
7. Official Pfizer prescribing information for Medrol notes a maintenance dose of 6–12 mg/day for severe RA and 2–6 mg/day for mild RA - the once-weekly approach represents a significantly lower cumulative dose and is thus favorable from a side-effect standpoint

Practical Summary

• Reduce to 4 mg once weekly after 2–3 months if disease is controlled
• Then 4 mg every 2 weeks for 4 more weeks
• Then stop
• Total steroid exposure is minimal; HPA suppression is not a concern at these doses/frequencies

Central Serous Chorioretinopathy (CSCR)

Definition & Pathophysiology

Epidemiology & Risk Factors

• Exogenous corticosteroids (any route - oral, inhaled, nasal spray, topical skin creams, intravitreal) - the most important modifiable risk factor
• Endogenous hypercortisolism - Cushing syndrome, adrenal adenoma
• Psychological stress / type A personality
• Systemic hypertension
• Sleep apnea syndrome
• Pregnancy
• Helicobacter pylori infection
• Renal dialysis
• Lupus (SLE)
• Genetic: SNP in complement factor H gene (chromosome 1) predisposes to chronic form in White individuals

Clinical Features

Symptoms

• Unilateral blurred/dim central vision
• Metamorphopsia (distortion)
• Micropsia (objects appear smaller)
• Mild dyschromatopsia (color desaturation)
• Central scotoma (relative)
• May be asymptomatic

Signs

• Visual acuity: typically 20/20 to 20/200 (6/9 to 6/18)
• Acquired hypermetropia - VA improves with +1 dioptre convex lens (due to retinal elevation)
• Round/oval serous detachment of neurosensory retina at the macula, with sloping margins
• Subretinal fluid (clear or turbid)
• One or more small pigment epithelial detachments (PEDs) within the detachment
• Precipitates on posterior retinal surface
• RPE atrophy/hyperplasia at sites of old lesions (visible on FAF)
• Gravitational tract - fluid tracking inferiorly (best seen on FAF)

Classification

Investigations

1. OCT (most important clinical tool)

• Underlying PEDs
• Subretinal precipitates/fibrin
• Choroidal thickening (enhanced-depth imaging OCT / EDI-OCT) - hallmark of pachychoroid
• Photoreceptor/RPE degeneration in chronic cases

EDI-OCT: neurosensory detachment with subretinal fluid and thickened choroid (Wills Eye Manual)

2. Fluorescein Angiography (FA/IVFA)

• Early hyperfluorescent spot at RPE leak site
• Two classic patterns:
  • "Ink blot" (most common) - spot enlarges centrifugally
  • "Smoke-stack" (10–20% of cases) - vertical column of dye rising upward, then spreading laterally - nearly pathognomonic

FA: classic "smoke-stack" pattern of leakage - Wills Eye Manual

3. ICGA (Indocyanine Green Angiography)

• Dilated/compromised outer choroidal vessels
• Mid-phase multifocal hyperfluorescent patches (choroidal hyperpermeability)
• Reveals subclinical foci not visible on FA
• Useful to identify leaking sites before PDT

4. FAF (Fundus Autofluorescence)

• Decreased autofluorescence at leakage site
• Gravitational tract pattern
• Old RPE atrophy visible

5. Amsler Grid

• Confirms metamorphopsia and relative scotoma area

6. Systemic workup in chronic CSCR

• Cortisol levels (rule out Cushing), renal function

Differential Diagnosis

Course & Prognosis

• Spontaneous resolution in ~80% within 3–6 months
• Return to near-normal or normal vision in most
• Recurrence in up to 50%
• ~15% follow a chronic course (>12 months) - risk of permanent photoreceptor/RPE damage and reduced VA
• Complications: CNV (choroidal neovascularization), RPE tears, cystoid macular degeneration

Management

1. Observation

2. Stop corticosteroids (if possible)

• Discontinue all forms - oral, topical, nasal, inhaled, intravitreal
• TIP from Kanski's: "All forms of corticosteroid treatment should be discontinued if possible in patients with chronic or recurrent CSCR."
• This is the single most important step when steroids are implicated

3. Laser Photocoagulation (conventional)

• May accelerate visual recovery but no proven long-term benefit
• Identifies and treats the RPE leak point on FA
• Risk: CNV formation - use only low-intensity laser
• Indications:
  • Persistent SRF for several months
  • Recurrence in an eye with permanent prior visual deficit
  • Fellow eye involvement after permanent deficit
  • Occupational necessity (e.g., pilots, drivers)

4. Subthreshold Micropulse Diode Laser

• Laser applied to RPE leak site without visible burn
• Good results; significantly less retinal damage on OCT than conventional photocoagulation
• Preferred over conventional laser in most centers

5. Photodynamic Therapy (PDT) with Verteporfin

• Treatment of choice for chronic CSCR
• Half-dose / reduced-fluence PDT (30–50% of standard MNV dose, 50% light intensity) - leads to complete resolution including severe chronic cases
• Lower incidence of choroidal ischemia vs. full-dose PDT
• Also considered for rapid SRF resolution in acute CSCR
• Mechanism: reduces choroidal hyperpermeability

6. Mineralocorticoid Receptor Antagonists (MRAs)

• Eplerenone and spironolactone (oral spironolactone 40 mg BD)
• Reduce choroidal vascular hyperpermeability by blocking mineralocorticoid receptors
• Associated with improved anatomic and visual outcomes in chronic CSCR
• A 2025 meta-analysis (PMID 40513762) of 13 studies found MRAs offer short-term benefits in reducing subretinal fluid (faster resolution at 1 month) but PDT outperforms MRAs in long-term SRF reduction
• Spironolactone significantly reduced retinal thickness vs observation
• MRAs were comparable to subthreshold micropulse laser at last follow-up

7. Anti-VEGF (intravitreal)

• Bevacizumab alone is not helpful unless there is associated CNV
• Used in conjunction with PDT when CNV develops as a complication
• Not a first-line treatment for CSCR itself

8. Other agents (limited evidence)

• Aspirin, beta-blockers, mifepristone - case reports only; not standard of care

Management Algorithm

Acute CSCR (<3-4 months)
    ↓
Stop steroids + Observe for 3 months
    ↓
Resolved? → Review at 3-6 months
Not resolved / Chronic CSCR?
    ↓
Half-dose PDT (preferred)
  OR Subthreshold micropulse laser
  OR Oral MRA (eplerenone/spironolactone)
    ↓
CNV develops?
    ↓
Add intravitreal anti-VEGF

Key Points to Remember

1. CSCR = pachychoroid spectrum disorder - thick choroid is the underlying anatomical basis
2. Steroids (any route) are the most important treatable precipitant - always ask and always stop
3. Smoke-stack on FA is nearly pathognomonic (but seen in only 10–20%)
4. EDI-OCT showing subretinal fluid + choroidal thickening is the standard diagnostic tool
5. Most acute cases resolve without treatment; chronic cases need active intervention
6. Half-dose PDT is the most effective treatment for chronic CSCR
7. MRAs provide short-term SRF reduction but PDT remains superior long-term
8. Recurrence rate up to 50% - follow up is essential

Azathioprine & Sulfasalazine in Pregnancy

Overview - Safety Classification

SULFASALAZINE

Mechanism Relevant to Pregnancy

Teratogenicity

• Case reports of fetal malformations have been published
• However, a large meta-analysis showed no statistically significant increase in congenital anomalies after fetal exposure
• Overall considered safe for use in pregnancy

Key Practical Points

• Continue sulfasalazine throughout pregnancy - it is a good option for active inflammatory arthritis (RA, peripheral SpA) in pregnant women
• Mandatory: higher-dose folic acid supplementation
  • Standard pregnancy dose is 0.4–0.5 mg/day; women on sulfasalazine need more
  • Goldman-Cecil recommends 1 mg twice daily (2 mg/day total) for women on sulfasalazine who are pregnant or planning pregnancy
  • This compensates for impaired folate absorption and prevents neural tube defects

Lactation

• Compatible with breastfeeding
• One isolated case report of bloody diarrhea in a breastfed neonate - but this is rare and overall data support continued use
• Monitor neonate for GI symptoms

AZATHIOPRINE (AZA)

Mechanism Relevant to Pregnancy

• The placenta in humans cannot metabolize azathioprine to its active form 6-mercaptopurine (6-MP)
• This means little to no biologically active drug actually reaches the fetus - a key reason AZA is considered relatively safe
• Despite this, some 6-MP has been detected in fetal blood, so caution remains appropriate

Teratogenicity Data

• Case reports exist of neonates with: pancytopenia, combined immunodeficiency, chromosomal abnormalities, craniofacial malformations
• However, multiple large case series (including transplant registries) fail to show increased congenital anomaly rates
• Study of 189 azathioprine-exposed vs. 230 control pregnancies: no significant difference in major malformations (3.5% vs. 3.0%)
• Lower mean birth weight and gestational age in AZA group (possibly from preterm delivery or IUGR, not directly teratogenic)
• Conclusion: AZA does not increase risk of congenital anomalies above background rates

Obstetric Risks (Low-Moderate)

• PROM (premature rupture of membranes)
• SGA (small for gestational age)
• IUGR (intrauterine growth restriction)

Indications in Pregnancy

• Steroid-sparing agent for RA, SLE, vasculitis during pregnancy
• Often used to replace mycophenolate (which is teratogenic) in women with lupus nephritis or transplant who become pregnant
• Standard doses used: 1–2 mg/kg/day (same as non-pregnant adults)

Lactation

• AZA is excreted in breast milk in low concentrations
• Considered compatible with lactation by most experts
• Active metabolites (6-MP, 6-TGN) are at low or unmeasurable levels in infant serum
• No adverse effects on infants up to 3 years of age in available data
• Long-term carcinogenesis data in infants are not available - discuss with patients

Comparative Summary Table

What to AVOID in Pregnancy (for context)

Practical Points for RA in Pregnancy

1. Plan pregnancy - switch from teratogenic DMARDs (MTX, leflunomide) to AZA or sulfasalazine before conception
2. Sulfasalazine is the first choice for peripheral RA/SpA in pregnancy if tolerated
3. Azathioprine is the first choice for immunosuppression in patients with lupus, vasculitis, or as a steroid-sparer
4. Start high-dose folic acid (2–5 mg/day) in any patient on sulfasalazine
5. Monitor CBC and LFTs regularly (both drugs) - unchanged from standard monitoring
6. Monitor fetal growth with serial USS from 20 weeks onwards in patients on AZA
7. Both drugs can be continued through all trimesters and during breastfeeding